Open AccessDaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study
Author(s) -
Sabrina G. Fabi,
Joel L. Cohen,
Lawrence J. Green,
Sunil Dhawan,
Theda C. Kontis,
Leslie Baumann,
Todd M. Gross,
Conor J. Gallagher,
Jessica Brown,
Roman G. Rubio
Publication year - 2020
Publication title -
dermatologic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.659
H-Index - 125
eISSN - 1524-4725
pISSN - 1076-0512
DOI - 10.1097/dss.0000000000002531
Subject(s) - medicine , wrinkle , placebo , clinical trial , severity of illness , botulinum toxin , open label , surgery , pathology , gerontology , alternative medicine
DaxibotulinumtoxinA for Injection (DAXI) is botulinum toxin Type A formulated with a novel peptide excipient. Two pivotal, single-treatment, placebo-controlled trials demonstrated efficacy and safety for moderate or severe glabellar lines.